Pagaya looks deeply undervalued following a 44.6% selloff despite robust growth. Click for more about PGY stock.

Xeris Biopharma is showing strong growth and improving EBITDA, especially driven by its blockbuster drug Recorlev. Learn why ...

Novo Nordisk stock slid after weak 2026 guidance and rising GLP-1 competition from Eli Lilly. Is NVO a buy on the dip?

Shares of Swiggy tumbled nearly 8 per cent on Friday on the back of weak quarterly earnings, which has led to price target ...

Food and beverage company PepsiCo (NASDAQ:PEP) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales ...

Eli Lilly execs believe the first oral version of their blockbuster GLP-1 drugs won't cannibalize sales of the injectables ...

Blend Labs Inc trading in (NYSE:BLND) recently drew attention following a sharp month-over-month decline, extending a longer ...

Record Bethania output puts Kuya Silver in focus Kuya Silver (CNSX:KUYA) has drawn fresh investor attention after reporting ...

HANGZHOU, ZHEJIANG PROVINCE, CHINA, January 16, 2026 /EINPresswire.com/ -- The wedding furniture manufacturing sector ...

The global nutraceuticals market, valued at approximately USD 416 billion in 2026, is projected to grow at a CAGR of around 9% over the next five years.Key factors driving this growth include ...

Asian markets traded mixed, while the stock market ended lower overnight after a sell-off in technology stocks. Sentiment in the domestic market remains upbeat after the announcement of the India-US ...

As India’s paints and coatings market progresses toward an estimated size of USD 18.21 billion by 2030, rural India will play a defining role in shaping the category’s future ...